We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $177M
1-Year Est. Return 212.06%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+212.06%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$177M
AUM Growth
-$804M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
4
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
+$793M
2
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
1
Phathom Pharmaceuticals
PHAT
$692M
$81M 45.65%
7,464,572
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.34B
$74.9M 42.19%
2,208,639
-465,543
AURA icon
3
Aura Biosciences
AURA
$826M
$21.6M 12.16%
3,039,892
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-19,963,157

Similar funds

ACM
Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
NRWA
North Ridge Wealth Advisors Beaverton, Oregon $178M AUM 12.81% 1-Year Est. Return
SMTF
Sphera Management Technology Funds Tel Aviv, Israel $178M AUM 42.1% 1-Year Est. Return
AGC
Alden Global Capital Brandon, Florida $177M AUM 32.31% 1-Year Est. Return
CTC
Cetera Trust Company St. Paul, Minnesota $177M AUM 28.75% 1-Year Est. Return
CNWM
Clay Northam Wealth Management Huntington Beach, California $178M AUM 26.61% 1-Year Est. Return
PS
Presima Securities Montreal, Quebec, Canada $178M AUM 1.26% 1-Year Est. Return

Medicxi Ventures Management's Q2 2026 Portfolio in Review

As of Q2 2026, Medicxi Ventures Management held 4 positions worth $177M, down 82% from $982M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $808M in Q2 2026, closing 1 position and reducing 1 holding. Its most notable exit was Centessa Pharmaceuticals, an estimated $793M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's biggest Q2 2026 reduction was NewAmsterdam Pharma, cutting an estimated $15.3M.
  • Medicxi Ventures Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $793M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $177M portfolio in Q2 2026.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q2 2026.
  • Medicxi Ventures Management's portfolio value fell 82% quarter-over-quarter to $177M.

Based on Medicxi Ventures Management's 13F filing for Q2 2026, filed 4 Aug 2026.